Literature DB >> 27208511

Hospital utilization outcome of an assertive outreach model for schizophrenic patients - results of a quasi-experimental study.

Dorothea Büchtemann1, Denise Kästner2, Ingeborg Warnke3, Jeanett Radisch1, Johanna Baumgardt4, Steffi Giersberg1, Katja Kleine-Budde1, Jörn Moock1, Wolfram Kawohl5, Wulf Rössler6.   

Abstract

We assessed whether an Assertive Outreach (AO) program for patients with schizophrenia implemented in German routine care in rural areas reduces psychiatric hospital admissions and/or psychiatric hospital days. We conducted a quasi-experimental controlled study with 5 assessments in 12 months. Data collection included health care utilization (Client Sociodemographic and Service Receipt Inventory), and clinical parameters. The assessments took place in the practices of the psychiatrists. Admission incidence rates were calculated. For bivariate group comparison, we used U-tests, T-tests and Chi(2)-Tests, multivariate analysis was conducted using zero-inflated regression models. For hospital outcomes, data of 295 patients was analysed. No statistically significant differences between AO and TAU patients in terms of hospital admissions or hospital days were found. Overall hospital utilization was low (8%). Advantages of AO over TAU referring to hospital utilization were not found. However, a spill-over effect might have reduced hospital utilization in both groups. Further research should differentiate patient subgroups. These two appear to be key factors to explain effects or absence of effects and to draw conclusions for the mental health care delivery.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Germany; Integrated care; Schizophrenia

Mesh:

Year:  2016        PMID: 27208511     DOI: 10.1016/j.psychres.2016.05.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Policies, guideline implementation and practice change - how can the process be understood?

Authors:  T Becker; R Kilian; M Kösters
Journal:  Epidemiol Psychiatr Sci       Date:  2016-10-19       Impact factor: 6.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.